Skip to Content

Esbriet (pirfenidone) Disease Interactions

There are 3 disease interactions with Esbriet (pirfenidone):

Moderate

Pirfenidone (Includes Esbriet) ↔ hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Increases in ALT and AST (>3 x ULN) with or without concomitant elevations in bilirubin, have been reported in patients treated with pirfenidone. These findings were reversible with dose modification or treatment discontinuation. Conduct liver tests prior to therapy initiation in all patients, then monthly for the first 6 months and every 3 months thereafter. Dose modification or interruption may be necessary for liver enzyme elevations. Pirfenidone should be used with caution in patients with mild to moderate hepatic impairment, monitoring adverse reactions. The safety and efficacy of pirfenidone has not been studied in patients with severe hepatic impairment, and is not recommended for use in these patients.

Moderate

Pirfenidone (Includes Esbriet) ↔ renal impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

Pirfenidone should be used with caution in patients with mild, moderate, or severe renal impairment, monitoring for adverse reactions and considering dosage modifications or discontinuation as needed. The safety and efficacy of pirfenidone has not been studied in patients with end-stage renal disease requiring dialysis, so its use is not recommended in these patients.

Moderate

Pirfenidone (Includes Esbriet) ↔ smoking

Moderate Potential Hazard, Moderate plausibility. Applies to: Smoking

Smoking causes decreased exposure to pirfenidone, which may alter its efficacy. Patients should be instructed to stop smoking prior to treatment, and to avoid smoking while taking pirfenidone.

Esbriet (pirfenidone) drug interactions

There are 121 drug interactions with Esbriet (pirfenidone)

Esbriet (pirfenidone) alcohol/food interactions

There is 1 alcohol/food interaction with Esbriet (pirfenidone)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide